| Recently, Suzhou Homesun Pharmaceutical Co., Ltd. (hereinafter referred to as “Homesun Pharmaceutical”), received approval letters from the National Medical Products Administration (NMPA) for their products Levofloxacin Tablets (0.5 g), Amiodarone Hydrochloride Injection (3 mL:150 mg), and Acetylcysteine Solution for Inhalation (3 mL:0.3 g).Levofloxacin Tablets are a fluoroquinolone antibiotic used to treat community-acquired pneumonia and nosocomial pneumonia caused by sensitive bacteria in adults, acute bacterial sinusitis, acute exacerbations of chronic bronchitis, complicated and uncomplicated skin and soft tissue infections, chronic bacterial prostatitis, complicated and uncomplicated urinary tract infections, acute pyelonephritis, and inhalational anthrax (post-exposure).Amiodarone Hydrochloride Injection is indicated for the treatment of severe arrhythmias when oral administration is not appropriate, especially for atrial arrhythmias with rapid ventricular response, tachycardia associated with Wolff-Parkinson-White (W-P-W) syndrome, severe ventricular arrhythmias, and for cardiopulmonary resuscitation in cases of ventricular fibrillation that are unresponsive to external defibrillation.Acetylcysteine Solution for Inhalation is a mucolytic agent with strong mucus-dissolving properties, primarily used to treat respiratory diseases characterized by excessive thick mucus secretion, such as acute bronchitis, chronic bronchitis and its exacerbations, emphysema, mucus obstruction syndrome, and bronchiectasis.During the marketing authorization application process, Yeedozencom conducted thorough reviews and assessments of the registration dossiers in accordance with regulatory and technical review standards. We also provided guidance to the client in improving supplemental materials, ensuring the smooth progress of the project, which ultimately led to the approval for marketing.As a long-term partner of Homesun Pharmaceutical, Yeedozencom is honored to work with such a socially responsible and innovative company. We firmly believe that through our joint efforts, more high-quality drugs will be developed in the future to benefit more patients and contribute to the healthy China. |
